Possible involvement of advanced glycation end products in carry-over benefits of atorvastatin in ASCOT-BPLA I read with interest the recent study by Sever et al., 1 which reported that patients originally assigned atorvastatin continued to demonstrate lower event rates in most cardiovascular endpoints after the termination of Lipid Lowering Arm of the ASCOT (ASCOT-LLA) trial, compared with those originally assigned placebo, although LDL-cholesterol levels were almost identical in the two groups during the 2 years extended follow-up period. 1 These observations suggest sustained cardioprotective effects of atorvastatin after the cessation of active treatment in at-risk patients with hypertension. A similar outcome was reported in the DCCT-EDIC Research; it revealed that original intensive therapy for 6.5 years reduced the risk of cardiovascular events to about 50% of that of conventional treatment in diabetic patients 11 years after the end of the trial, although glycosylated haemoglobin values in the two groups had almost converged during the follow-up periods. 2 Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study
We read with interest the article by Schnabel et al. 1 in which the authors assessed the prognostic value of baseline levels of adiponectin in patients with manifest coronary artery disease (CAD). They conclude that adiponectin concentration is predictive of cardiovascular death or non-fatal myocardial infarction (MI) at a median follow-up of 2.5 years. Several considerations are worth noting before accepting these conclusions.
First, the overall study population is markedly heterogeneous due to the inclusion of patients with stable angina (SA) and various sub-sets of patients with acute coronary syndromes (ACS) (e.g. ST-elevation and non-ST elevation MI). While baseline adiponectin levels were almost comparable in both SA and ACS patients, the levels of B-type natriuretic peptide (BNP) and of C-reactive protein (CRP) were more than two-fold higher in patients with ACS than in SA. Both BNP and CRP are known to be associated with adverse outcome in ACS patients 2, 3 with BNP also having a prognostic role in patients with SA. 4, 5 The BNP levels in the present study were only 38 pg/mL (11.94-99.81) in patients with SA, a range comparable with 36.1 pg/mL (11.3 -94.6), a value found in patients with SA who did not have cardiovascular events in a previous study 4 and overlapping with the values of the first and partially the second lower quartiles of BNP, which were not associated with increased risk of cardiovascular events. 5 Secondly, despite continuous levels of adiponectin predicting cardiovascular events in the overall population after adjusting for the presence of ACS (model 2 regression), adiponectin was not significantly associated with the outcome (models 1 -4) in patients with ACS, while only in patients with SA predicted the outcome. Thirdly, the authors did not report the cardiovascular event rate according to SA and ACS, but it is likely that the patients with SA in this study (who had low BNP values) had a better prognosis compared with patients with ACS.
Taken together, these finding raise the strong possibility that an association between adiponectin and prognosis in patients with ACS might not exist, and that the main result of this study may have been driven by the patients with SA. As patients with ACS represent a large part of patients with CAD in clinical practice, the conclusion, therefore, that adiponectin predicts outcome in patients with CAD may be not accurate.
Moreover, the independent predictive value of adiponectin in SA patients might be a spurious finding, as patients with SA and high levels of BNP (.100 pg/mL) were not included in this study. Furthermore, even in the present cohort of SA patients, a hazard ratio ¼ 1.035 may not represent a clinically significant increase in adverse events if the baseline absolute risk of events is low anyway.
Finally, continuous levels of adiponectin did not independently predict the outcome in the overall population and the independent predictive value of a one-quartile adiponectin level increase has not been verified after entering BNP, CRP, and creatinine as covariates in the Cox proportional hazard regression model.
